CXCR2 antagonists are currently in clinical trials to block MDSC recruitment to tumors and the pre-metastatic niche (NCT03177187 in metastatic castration-resistant prostate cancer (not yet recruiting). This evidence concerns the gene CXCR2 and Familial prostate cancer.